H.C. Wainwright Keeps Their Buy Rating on Anavex Life Sciences (AVXL)

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Anavex Life Sciences (AVXLResearch Report), with a price target of $42.00. The company’s shares closed last Monday at $9.88, close to its 52-week low of $7.13.

According to TipRanks.com, Selvaraju ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -41.3% and a 14.2% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Santhera Pharmaceuticals Holding AG, MoonLake Immunotherapeutics, and Oncternal Therapeutics.

Currently, the analyst consensus on Anavex Life Sciences is a Strong Buy with an average price target of $35.20, which is a 227.1% upside from current levels. In a report issued on July 19, Berenberg Bank also maintained a Buy rating on the stock with a $40.00 price target.

See today’s best-performing stocks on TipRanks >>

The company has a one-year high of $23.73 and a one-year low of $7.13. Currently, Anavex Life Sciences has an average volume of 940.7K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer’s and Parkinson’s disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.

Read More on AVXL:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More